心力衰竭治疗新靶点—Galectins-3  

Galectin-3 is a novel therapeutic target in heart failure

作　　者：郑刚[1] 

机构地区：[1]天津市第三医院心内科天津市老年病研究所,天津300250

出　　处：《世界临床药物》2014年第6期I0009-I0011,共3页World Clinical Drug

摘　　要：尽管心力衰竭(HF)的药物治疗近年来有了较大进展,但HF患者预后仍很差。针对HF发病早期行药物治疗是近年来研究的一个重点。Galectin-3(Gal-3)在心室重塑和HF病理生理发展过程中起重要作用,可作为HF治疗的靶点。Gal-3水平升高的HF患者可从醛固酮拮抗剂治疗中获益。本文简要综述以Gal-3水平为指导的HF患者个体化治疗。Although medications of heart failure （HF） have made great progress in recent years, there is still a poor prognosis in patients with HF. Drug therapeutics in early stage of HF is a research focus in recent years. Galectin-3 （Gal-3） plays an important role in the ventricular remodeling and pathophysiology process of HF, which can be used as HF therapeutic target. The heart failure patients, who have the antagonist therapy. raised levels of galectin-3 can be beneficial from aldosterone

关 键 词：GALECTIN-3 心力衰竭 药物治疗 临床研究 

分 类 号：R972[医药卫生—药品] R541.6[医药卫生—药学]